

**Fiscal Year 2026 Congressionally Directed Medical Research Programs
Parkinson's Research Program (PRP)
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Early Investigator Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526PRPEIRA</p>	<p>Postdoctoral fellow, clinical fellow, or independent investigator within 10 years of advanced degree or residency training completion, or equivalent.</p> <p>Requires verification of eligibility criteria in an Eligibility Statement signed by an appropriate institutional official and the principal investigator (PI).</p>	<ul style="list-style-type: none"> • Supports Parkinson's disease (PD) research opportunities for investigators in the early stages of their careers; however, the investigator need not have previous Parkinson's disease research experience. • Research must address one of the FY26 PRP focus areas. • <i>Each funding level supports investigators of a particular career status.</i> <ul style="list-style-type: none"> ○ Funding Level 1: Applications may name early-career investigators at the postdoctoral level, including clinical fellows, or equivalent, as the PI. Applications <i>must</i> include at least one mentor appropriate to the proposed research project who has experience in PD research and mentoring. <ul style="list-style-type: none"> – Preliminary data are encouraged. ○ Funding Level 2: Applications may name early-career, independent investigators within 10 years of advanced degree or residency training completion, or equivalent, as the PI. Applications do not require a mentor. <ul style="list-style-type: none"> – Preliminary data are required. • Clinical trials are not allowed. • Submission of a Letter of Intent is required prior to full application submission. 	<p>Funding Level 1:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$300,000 for total costs.* • The maximum period of performance is 2 years. <p>Funding Level 2:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.0 million (M) for total costs.* • The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): October 23, 2026 5:00 p.m. Eastern time</p> <p>Application: November 6, 2026 11:59 p.m. Eastern time</p> <p>Confidential Letters of Recommendations: November 13, 2026 5:00 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526PRPIIRA</p>	<p>Independent investigators at all academic levels, or equivalent.</p>	<ul style="list-style-type: none"> • Supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to PD research. • Supports the full spectrum of research from basic pre-clinical science through clinical trials. • Research must address one of the FY26 PRP focus areas. • Partnering PI Option: Multiple investigators may collaborate on a single project, each of whom will be recognized as a PI and receive a separate award. • <i>Preliminary data are required.</i> • <i>Submission of a Letter of Intent is required prior to full application submission.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.0M for total costs.* • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): October 23, 2026 5:00 p.m. Eastern time</p> <p>Application: November 6, 2026 11:59 p.m. Eastern time</p>

*Total costs include direct and indirect costs.